# Observational Neoplasm, Residual studies: 43 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 43 trials that are observational for Neoplasm, Residual that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting observational Neoplasm, Residual studies: 43 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/observational/neoplasm-residual

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 43
- Recruiting or not yet: 43
- Read on: November 19, 2026

## Trials

The 25 newest of 43, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 6, 2026 | NCT07921888 | Patient-Specific MRD Liquid Biopsy in Resected NSCLC: Plasma and Bronchial Washing ctDNA | Sponsor not shown (see the record) | Observational | Recruiting | Non-Small Cell Lung Cancer, Minimal Residual Disease | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07921888) |
| November 5, 2026 | NCT07919119 | Risk Stratification Value of Deep NGS-MRD Detection in Acute Myeloid Leukemia Patients After Allo-HSCT | Institute of Hematology & Blood Diseases Hospital, China | Observational | Not yet recruiting | Measurable Residual Disease, Acute Myeloid Leukemia | 169 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919119) |
| August 10, 2026 | NCT07756437 | Validation of a Circulating Tumor DNA Blood Test in Muscle-Invasive Bladder and Upper Tract Urothelial Cancer | Sponsor not shown (see the record) | Observational | Recruiting | Muscle-Invasive Bladder Cancer (MIBC), Upper Tract Urothelial Carcinoma, Urothelial Carcinoma (UC) | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07756437) |
| August 3, 2026 | NCT07741435 | Methylation Profile Test (Methylscape) in Body Fluids for Multi-Cancer Detection and Monitoring in Colombia | Sponsor not shown (see the record) | Observational | Recruiting | Neoplasms, Solid Tumor, Breast Neoplasms, Lung Neoplasms, Stomach Neoplasms, Uterine Cervical Neoplasms, Colorectal... | 3,250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07741435) |
| July 8, 2026 | NCT07691034 | Monitoring MRD in Multiple Myeloma in Serum by Mass Spectrometry | Odense University Hospital | Observational | Not yet recruiting | Multiple Myeloma, Minimal Residual Disease | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07691034) |
| June 26, 2026 | NCT07670962 | Blood-Based Minimal Residual Disease in Advanced Epithelial Ovarian Cancer After 1st Line Therapy | Asan Medical Center | Observational | Not yet recruiting | Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, Ovarian Cancer | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07670962) |
| June 18, 2026 | NCT07657325 | Study on MRD Prediction of Efficacy of Toripalimab in the Treatment of High-risk Recurrent Renal Carcinoma | Tianjin Medical University Second Hospital | Observational | Recruiting | Renal Cell Carcinoma (RCC) | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07657325) |
| May 19, 2026 | NCT07597252 | ctDNA Monitoring After Pancreatic Cancer Surgery (K-4CARE Lite Study) | Chang Gung Memorial Hospital | Observational | Not yet recruiting | Pancreatic Ductal Adenocarcinoma (PDAC), NGS Monitor MRD | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07597252) |
| April 13, 2026 | NCT07524114 | Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK) | University Health Network, Toronto | Observational | Recruiting | Breast Cancer, Lung Cancer, Melanoma, Gynecologic Cancer, Genitourinary Cancer, Pancreatobiliary Cancer... | 7,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07524114) |
| April 7, 2026 | NCT07514715 | Proof of Concept for Real-time Multicentric Monitoring of MRD by PET and ctDNA in Aggressive B-Cell Lymphomas | The Lymphoma Academic Research Organisation | Observational | Not yet recruiting | Aggressive B-cell Lymphomas | 129 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07514715) |
| March 30, 2026 | NCT07500441 | Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML | Peking University People's Hospital | Observational | Recruiting | Acute Myeloid Leukemia (AML) | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07500441) |
| March 19, 2026 | NCT07483476 | Study of Cell-free DNA in Children and Adolescents With Acute Lymphoblastic Leukemia | Assistance Publique - Hôpitaux de Paris | Observational | Recruiting | Acute Lymphoblastic Leukemia ALL | 205 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07483476) |
| March 6, 2026 | NCT07454486 | TRACE-BTC. Relation of Biomarkers and Patients Reported Quality of Life to Outcomes in Patients With Biliary Tract Cancer: a Real- World... | Aarhus University Hospital | Observational | Not yet recruiting | Biliary Tract Cancer (BTC), Biliary Tract Cancer (CCA), Gall Bladder Cancer, Biliary Tract Cancers (BTC)... | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07454486) |
| February 2, 2026 | NCT07382505 | Prospective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cervical Cancer | Asan Medical Center | Observational | Not yet recruiting | Uterine Neoplasms, Cervical Cancer | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07382505) |
| January 21, 2026 | NCT07356882 | European Project for ctDNA Detection as a Biomarker for Non-invasive Therapy Monitoring in Paediatric Classical Hodgkin Lymphoma | Assistance Publique - Hôpitaux de Paris | Observational | Recruiting | Classical Hodgkin Lymphoma | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07356882) |
| December 18, 2025 | NCT07291921 | To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and Establish... | Peking University People's Hospital | Observational | Recruiting | Lung Neoplasms, Neoadjuvant Therapy, Immunotherapy, Minimal Residual Disease | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07291921) |
| December 8, 2025 | NCT07269067 | Automated vs Manual Flow-cytometry Gating for Measurable Residual Disease in Acute Myeloid Leukaemia (DUALFLOW) | University Hospital, Bordeaux | Observational | Not yet recruiting | Leukemia, Myeloid, Acute | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07269067) |
| October 7, 2025 | NCT07211178 | Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies | Tempus AI | Observational | Recruiting | Breast Cancer, TNBC - Triple-Negative Breast Cancer, HR Positive/HER-2 Negative Breast Cancer, HER2 + Breast Cancer... | 900 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07211178) |
| August 8, 2025 | NCT07112612 | Minimal Residual Disease Used in Predicting Therapeutic Efficacy in Metastatic Hormone-sensitive Prostate Cancer | Anhui Medical University | Observational | Not yet recruiting | MRD, Prostate Cancer, mHSPC | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07112612) |
| July 1, 2025 | NCT07045168 | Risk-adapted Therapeutic Strategy in +1q NDMM | Sponsor not shown (see the record) | Observational | Not yet recruiting | Multiple Myeloma | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07045168) |
| May 9, 2025 | NCT06963307 | Novel Epigenetic Mapping in Cell-Free DNA for the Detection of Lung Cancer | JaxBio Ltd | Observational | Recruiting | Lung Cancer, Non-Small Cell | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06963307) |
| April 24, 2025 | NCT06941987 | Evaluate the Clinical Feasibility of a Novel Neoantigen-Reactive CD8+ T Cell (NART) Detection Technology for Postoperative MRD Surveillance... | Shanghai Zhongshan Hospital | Observational | Not yet recruiting | Minimal Residual Disease, Pancreatic Cancer Resectable | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06941987) |
| March 13, 2025 | NCT06875609 | ctDNA in Cutaneous Squamous Cell Carcinoma | Massachusetts Eye and Ear Infirmary | Observational | Recruiting | Cutaneous Squamous Cell Carcinoma | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06875609) |
| March 3, 2025 | NCT06854939 | A Prospective Study Investigating the Relationship Between Minimal Residual Disease Detection, Monitoring Frequency, and Prognosis in... | National Cancer Center, Japan | Observational | Not yet recruiting | NSCLC, Stage I, II, III | 350 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06854939) |
| July 23, 2024 | NCT06514118 | Chemoimmunotherapy Plus Residual Lesion Irradiation for the Treatment of Extensive Stage Small-cell Lung Cancer | Qingdao Central Hospital | Observational | Recruiting | Small-cell Lung Cancer, Residual Tumor, Radiation | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06514118) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Assistance Publique - Hôpitaux de Paris | 3 |
| University Hospital, Montpellier | 3 |
| Peking University People's Hospital | 3 |
| Asan Medical Center | 2 |
| University Health Network, Toronto | 2 |
| Lund University | 1 |
| Caris Science, Inc. | 1 |
| JaxBio Ltd | 1 |
| Tianjin Medical University Second Hospital | 1 |
| The Lymphoma Academic Research Organisation | 1 |
| Jiangsu Cancer Institute & Hospital | 1 |
| Institute of Hematology & Blood Diseases Hospital, China | 1 |
| Hebei Medical University Fourth Hospital | 1 |
| Munich Leukemia Laboratory | 1 |
| University Hospital, Bordeaux | 1 |
| Tempus AI | 1 |
| Qingdao Central Hospital | 1 |
| Instituto do Cancer do Estado de São Paulo | 1 |
| Aarhus University Hospital | 1 |
| RenJi Hospital | 1 |
| First Affiliated Hospital of Zhejiang University | 1 |
| Anhui Medical University | 1 |
| Shanghai Zhongshan Hospital | 1 |
| Odense University Hospital | 1 |
| Chang Gung Memorial Hospital | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 13 |
| France | 9 |
| United States | 4 |
| Germany | 3 |
| Sweden | 2 |
| South Korea | 2 |
| Denmark | 2 |
| Canada | 2 |
| Israel | 1 |
| Colombia | 1 |
| Brazil | 1 |
| Belgium | 1 |
| Austria | 1 |
| Taiwan | 1 |
| Netherlands | 1 |
| Japan | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Footwear wholesalers in the United States](https://specstream.ai/data/businesses/footwear-wholesalers/united-states)
- [Taiwanese restaurants in the United States](https://specstream.ai/data/businesses/taiwanese-restaurants/united-states)
- [Fence contractors in the United States](https://specstream.ai/data/businesses/fence-contractors/united-states)
- [Spine surgery practices in the United States](https://specstream.ai/data/businesses/spine-surgery-practices/united-states)
- [Environmental services in the United States](https://specstream.ai/data/businesses/environmental-services/united-states)
- [Shutters companies in the United States](https://specstream.ai/data/businesses/shutters-companies/united-states)
